A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's Macroglobulinemia
Latest Information Update: 19 Jul 2024
Price :
$35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Bendamustine (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms BRAWM
- 12 Dec 2023 Initial results(N=44) assessing efficacy and safety of Bendamustine, rituximab and acalabrutinib front-line therapy for Waldenstroms macroglobulinaemia (WM) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results (n=10) assessing efficacy and tolerability of Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstroms Macroglobulinemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 17 Mar 2021 Status changed from not yet recruiting to recruiting.